Shared on 14 Dec 25Fair value Increased 8.55%NVCR: Long-Term Pipeline And Margin Outlook Will Support Upside PotentialAnalysts have modestly raised their fair value estimate for NovoCure from $38.00 to about $41.25 per share, reflecting updated models that balance increased long term conservatism with slightly stronger profit margin expectations and a higher future earnings multiple. Analyst Commentary Analyst sentiment on NovoCure remains mixed, but recent updates show a constructive undertone even as some models become more conservative.Read more0 votesShare